iBio, Inc. Files 8-K: Material Definitive Agreement

TL;DR

iBio filed an 8-K for a new material agreement, details to follow.

AI Summary

On July 3, 2024, iBio, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, but specific details of the agreement or financial figures were not provided in the initial filing information.

Why It Matters

This filing indicates a significant new agreement for iBio, Inc., which could impact its business operations and financial future.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the impact of which is not yet fully understood.

Key Players & Entities

• iBio, Inc. (company) — Registrant
• July 3, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share IBIO NYSE America
• $7,350,000 — the Registration Statement is currently $7,350,000, which is based on the limitations of G
• $75,000 — ts of counsel to the Sales Agents up to $75,000 plus (i) an additional $5,000 per quart
• $5,000 — ts up to $75,000 plus (i) an additional $5,000 per quarter so long as the ATM Agreemen
• $25,000 — ection 4 of the ATM Agreement, and (ii) $25,000 in connection with any filing of an add

Filing Documents

• tm2418848d1_8k.htm (8-K) — 32KB
• 0001104659-24-077791.txt ( ) — 203KB
• ibio-20240703.xsd (EX-101.SCH) — 3KB
• ibio-20240703_lab.xml (EX-101.LAB) — 33KB
• ibio-20240703_pre.xml (EX-101.PRE) — 22KB
• tm2418848d1_8k_htm.xml (XML) — 4KB

01. Entry

Item 1.01. Entry Into a Material Definitive Agreement. On July 3, 2024, iBio, Inc., a Delaware corporation (the "Company"), entered into an At Market Issuance Sales Agreement (the "ATM Agreement") with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC (the "Sales Agents") providing for the sale by the Company of its shares of common stock, par value $0.001 per share (the "Common Stock"), from time to time, through the Sales Agents, with certain limitations on the amount of Common Stock that may be offered and sold by the Company as set forth in the ATM Agreement (the "Offering"). Offers and sales of shares of Common Stock by the Company, if any, under the ATM Agreement, is subject to the effectiveness of the Company's shelf registration statement on Form S-3 (File No. 333-280680) , filed with the Securities and Exchange Commission (the " SEC ") on July 3, 2024 (the " Registration Statement ") under the Securities Act of 1933, as amended (the " Securities Act "). The Company makes no assurances as to if or whether the Registration Statement will become effective or, if it does become effective, as to the continued effectiveness of the Registration Statement. The aggregate market value of the shares of Common Stock eligible for sale under the ATM prospectus supplement included in the Registration Statement is currently $7,350,000, which is based on the limitations of General Instruction I.B.6 of Form S-3. Pursuant to the ATM Agreement, the Company will set the parameters for the sale of shares of Common Stock, including the number of shares of Common Stock to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the ATM Agreement, the Sales Agents may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under

01. Financial

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 1.1 At Market Issuance Sales Agreement, dated July 3, 2024, by and among the Company, Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC (Incorporated herein by reference to Exhibit Number 1.1 to the Company's registration statement on Form S-3 (File No. 333-280680, as filed with the Securities and Exchange Commission on July 3, 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 3, 2024 IBIO, INC. By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: General Counsel and Corporate Secretary